BioMarin Pharmaceutical Inc.
BioMarin Pharmaceutical Inc. Fundamental Analysis
BioMarin Pharmaceutical Inc. (BM8.DE) shows moderate financial fundamentals with a PE ratio of 23.74, profit margin of 23.54%, and ROE of 9.31%. The company generates $2.1B in annual revenue with strong year-over-year growth of 17.97%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 74.8/100 based on profitability, valuation, growth, and balance sheet metrics. The B grade reflects solid fundamentals with room for improvement in valuation or growth.
Fundamental Health Score
We analyze BM8.DE's fundamental strength across five key dimensions:
Efficiency Score
WeakBM8.DE struggles to generate sufficient returns from assets.
Valuation Score
ExcellentBM8.DE trades at attractive valuation levels.
Growth Score
ModerateBM8.DE shows steady but slowing expansion.
Financial Health Score
ExcellentBM8.DE maintains a strong and stable balance sheet.
Profitability Score
ModerateBM8.DE maintains healthy but balanced margins.
Key Financial Metrics
Is BM8.DE Expensive or Cheap?
P/E Ratio
BM8.DE trades at 23.74 times earnings. This indicates a fair valuation.
PEG Ratio
When adjusting for growth, BM8.DE's PEG of 1.27 indicates fair valuation.
Price to Book
The market values BioMarin Pharmaceutical Inc. at 2.32 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 15.44 times EBITDA. This signals the market has high growth expectations.
How Well Does BM8.DE Make Money?
Net Profit Margin
For every $100 in sales, BioMarin Pharmaceutical Inc. keeps $23.54 as profit after all expenses.
Operating Margin
Core operations generate 29.66 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $9.31 in profit for every $100 of shareholder equity.
ROA
BioMarin Pharmaceutical Inc. generates $7.91 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
BioMarin Pharmaceutical Inc. produces operating cash flow of $498.78M, showing steady but balanced cash generation.
Free Cash Flow
BioMarin Pharmaceutical Inc. generates strong free cash flow of $449.76M, providing ample flexibility for dividends, buybacks, or growth.
FCF Per Share
Each share generates $2.37 in free cash annually.
FCF Yield
BM8.DE converts 3.86% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
23.74
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
1.27
vs 25 benchmark
P/B Ratio
Price to book value ratio
2.32
vs 25 benchmark
P/S Ratio
Price to sales ratio
5.53
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.10
vs 25 benchmark
Current Ratio
Current assets to current liabilities
5.56
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.09
vs 25 benchmark
ROA
Return on assets percentage
0.08
vs 25 benchmark
ROCE
Return on capital employed
0.11
vs 25 benchmark
How BM8.DE Stacks Against Its Sector Peers
| Metric | BM8.DE Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 23.74 | 28.54 | Better (Cheaper) |
| ROE | 9.31% | 738.00% | Weak |
| Net Margin | 23.54% | -43982.00% (disorted) | Strong |
| Debt/Equity | 0.10 | 0.34 | Strong (Low Leverage) |
| Current Ratio | 5.56 | 2806.01 | Strong Liquidity |
| ROA | 7.91% | -14624.00% (disorted) | Weak |
BM8.DE outperforms its industry in 4 out of 6 key metrics, particularly excelling in Net Margin, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews BioMarin Pharmaceutical Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
57.79%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
1786.42%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
1018.31%
Industry Style: Defensive, Growth, Innovation
High Growth